Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Recurrence × regorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 10 Carcinoma, Hepatocellular 6 Rectal Neoplasms 2 Liver Neoplasms 2 Glioblastoma 2 Colonic Neoplasms 2 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Recurrence 1 Patient Compliance 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Microsatellite Stable Metastatic Colorectal Cancer 1 Meningioma 1 Melanoma 1 MCRC 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Liver Metastases 1 Leiomyosarcoma 1 Histiocytoma, Malignant Fibrous 1 Hematologic Neoplasms 1

Interventions

venetoclax 19 Cyclophosphamide 17 pembrolizumab 15 Dexamethasone 14 Cytarabine 12 fludarabine 11 Azacitidine 10 Gemcitabine 9 pomalidomide 7 Rituximab 7 Carboplatin 7 selinexor 6 glofitamab 6 Temozolomide 6 Lenalidomide 6 Granulocyte Colony-Stimulating Factor 6 fludarabine phosphate 5 Paclitaxel 5 Oxaliplatin 5 Injections 5 Cisplatin 5 zanubrutinib 4 ruxolitinib 4 obinutuzumab 4 daratumumab 4 carfilzomib 4 Surgical Procedures, Operative 4 Nivolumab 4 Decitabine 4 Cladribine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03970447 2025-09-09

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡